Farther Finance Advisors’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.5K Sell
2,087
-377
-15% -$3.15K ﹤0.01% 4071
2026
Q1
$20.6K Sell
2,464
-3,699
-60% -$38.3K ﹤0.01% 3632
2025
Q4
$76.2K Buy
6,163
+4,827
+361% +$51.7K ﹤0.01% 2520
2025
Q3
$11.8K Buy
1,336
+861
+181% +$6.7K ﹤0.01% 3371
2025
Q2
$3.03K Sell
475
-3,195
-87% -$18.3K ﹤0.01% 3551
2025
Q1
$17.4K Buy
3,670
+3,175
+641% +$26.3K ﹤0.01% 2455
2024
Q4
$4.73K Sell
495
-60
-11% -$551 ﹤0.01% 2694
2024
Q3
$4.63K Sell
555
-69
-11% -$627 ﹤0.01% 2680
2024
Q2
$4.41K Buy
624
+136
+28% +$585 ﹤0.01% 2452
2024
Q1
$1.12K Buy
488
+39
+9% +$88 ﹤0.01% 2726
2023
Q4
$1.08K Buy
449
+429
+2,145% +$1.01K ﹤0.01% 2695
2023
Q3
$68 Hold
20
﹤0.01% 2559
2023
Q2
$147 Hold
20
﹤0.01% 2399
2023
Q1
$207 Sell
20
-24
-55% -$290 ﹤0.01% 2193
2022
Q4
$520 Buy
+44
New +$681 ﹤0.01% 1824

Other funds holding EBS

Farther Finance Advisors's EBS Position: Q2 2026 in Review

Farther Finance Advisors reduced its Emergent Biosolutions (EBS) stake by 15% in Q2 2026, selling an estimated $3.15K and leaving 2,087 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

Farther Finance Advisors first reported a position in EBS in Q4 2022 and has held it in 15 quarters since. The position peaked at $76.2K in Q4 2025. 20 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Farther Finance Advisors held 2,087 shares of Emergent Biosolutions worth $17.5K as of Q2 2026.
  • Farther Finance Advisors sold 377 Emergent Biosolutions shares in Q2 2026, an estimated $3.15K.
  • Emergent Biosolutions made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4071 holding.
  • Farther Finance Advisors first reported a position in Emergent Biosolutions in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's Emergent Biosolutions position peaked at $76.2K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.